A randomized trial of budiodarone in paroxysmal atrial fibrillation
MD Ezekowitz, R Nagarakanti, A Lubinski… - Journal of interventional …, 2012 - Springer
Objective The aim of this study was to investigate the preliminary safety and efficacy of three
doses of budiodarone in patients with paroxysmal atrial fibrillation. Background …
doses of budiodarone in patients with paroxysmal atrial fibrillation. Background …
Retrometabolism‐based drug design and targeting
N Bodor, P Buchwald - Burger's medicinal chemistry and drug …, 2003 - Wiley Online Library
Retrometabolic drug design (RMDD) approaches are systematic methodologies aimed to
design safe compounds with an improved therapeutic index. RMDDs thoroughly integrate …
design safe compounds with an improved therapeutic index. RMDDs thoroughly integrate …
The effect of C-reactive protein reduction with a highly specific antisense oligonucleotide on atrial fibrillation assessed using beat-to-beat pacemaker Holter follow-up
C Sugihara, N Freemantle, SG Hughes… - Journal of Interventional …, 2015 - Springer
Purpose C-reactive protein (CRP) is known to be strongly associated with atrial fibrillation
(AF). However, it is not clear if CRP is a causal factor for AF. ISIS-CRP Rx is a novel …
(AF). However, it is not clear if CRP is a causal factor for AF. ISIS-CRP Rx is a novel …
New pharmacological targets and treatments for atrial fibrillation
L Carlsson, G Duker, I Jacobson - Trends in pharmacological sciences, 2010 - cell.com
Atrial fibrillation (AF) is an arrhythmia of growing clinical concern that is increasing in
prevalence and is associated with significant morbidity and mortality. Pharmacological …
prevalence and is associated with significant morbidity and mortality. Pharmacological …
Pharmacotherapy of atrial fibrillation: a pathophysiological perspective and review
S Jacob, OA Ali, V Pidlaoan, AO Badheka… - American journal of …, 2011 - journals.lww.com
Atrial fibrillation (AF) is one of the most common arrhythmia encountered in clinical practice.
Although AF is due to the structural and electrophysiological alterations in the atria, its …
Although AF is due to the structural and electrophysiological alterations in the atria, its …
The pharmaceutical pipeline for atrial fibrillation
P Santangeli, LD Biase, G Pelargonio… - Annals of …, 2011 - Taylor & Francis
Atrial fibrillation (AF) is associated with a significant burden of morbidity and increased risk
of mortality. Beyond outstanding advances in catheter ablation procedures, antiarrhythmic …
of mortality. Beyond outstanding advances in catheter ablation procedures, antiarrhythmic …
Recent advances in retrometabolic drug design (RMDD) and development
N Bodor, P Buchwald - Die Pharmazie-An International Journal …, 2010 - ingentaconnect.com
As a general review for the 7th Retrometabolism-Based Drug Design and Targeting
Conference, recent developments within this field are briefly reviewed with various …
Conference, recent developments within this field are briefly reviewed with various …
Methods for treating atrial fibrillation
PG Milner, DJ Ellis - US Patent 9,549,912, 2017 - Google Patents
A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, eg
fungichromin having five-membered rings with one oxygen as the only ring hetero atom, eg …
fungichromin having five-membered rings with one oxygen as the only ring hetero atom, eg …
Atrial fibrillation-the final frontier
M Govindan, I Savelieva… - Journal of …, 2010 - journals.sagepub.com
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and represents a
significant health care issue. The diagnosis and management of AF uses a significant …
significant health care issue. The diagnosis and management of AF uses a significant …